Sacituzumab Tirumotecan Plus Pembrolizumab Meets Phase III Endpoint in First-Line PD-L1-Negative Non-Squamous NSCLC

2 articles · 2 sources · updated 12 hours ago

Recent

OncoDailySacituzumab Tirumotecan Plus Pembrolizumab Meets Phase III Endpoint in First-Line PD-L1-Negative Non-Squamous NSCLC12 hours ago

0

Manila TimesKelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint2 days ago · By PR Newswire

0